Exelixis (EXEL) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $62.83, +3.02% vs the prior close of $60.99.
- Volume 2.77M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
EXEL jumps 3.0% to $62.83, a 52-week high. Closed at $62.83, +3.02% vs the prior close of $60.99. Day range $61.28–$63.31, opened at $61.69.
EXEL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — EXEL jumps 3.0% to $62.83, a 52-week high
- Closed at $62.83, +3.02% vs the prior close of $60.99. Day range $61.28–$63.31, opened at $61.69.
- Volume was 2.77M shares, 1.2x its 50-day average of 2.36M.
- Price is +11.0% vs its 50-day average ($56.59) and +26.3% vs its 200-day average ($49.76).
- 52-week range $33.76–$63.31; today's close sits at 98% of that range, 0.8% below the 52-week high.
Oct 14, 2026 — EXEL rises 2.5% to $60.99, a 52-week high
- Closed at $60.99, +2.49% vs the prior close of $59.51. Day range $59.56–$61.18, opened at $59.92.
- Volume was 2.75M shares, 1.2x its 50-day average of 2.36M.
- Price is +8.0% vs its 50-day average ($56.47) and +22.8% vs its 200-day average ($49.67).
- 52-week range $33.76–$61.66; today's close sits at 98% of that range, 1.1% below the 52-week high.
Oct 13, 2026 — EXEL dips 0.5% to $59.51
- Closed at $59.51, -0.52% vs the prior close of $59.82. Day range $58.59–$60.00, opened at $60.00.
- Volume was 2.62M shares, 1.1x its 50-day average of 2.39M.
- Price is +5.6% vs its 50-day average ($56.37) and +20.0% vs its 200-day average ($49.60).
- 52-week range $33.76–$61.66; today's close sits at 92% of that range, 3.5% below the 52-week high.
Oct 12, 2026 — EXEL ends flat (-0.1%) to $59.82
- Closed at $59.82, -0.07% vs the prior close of $59.86. Day range $59.80–$61.66, opened at $60.48.
- Volume was 3.13M shares, 1.3x its 50-day average of 2.39M.
- Price is +6.3% vs its 50-day average ($56.28) and +20.8% vs its 200-day average ($49.53).
- 52-week range $33.76–$61.66; today's close sits at 93% of that range, 3.0% below the 52-week high.
Oct 9, 2026 — EXEL rises 1.4% to $59.86, a 52-week high, 3 up days in a row
- Closed at $59.86, +1.42% vs the prior close of $59.02. Day range $59.00–$60.83, opened at $59.00.
- Volume was 2.67M shares, 1.1x its 50-day average of 2.39M.
- Price is +6.6% vs its 50-day average ($56.14) and +21.0% vs its 200-day average ($49.47).
- 52-week range $33.76–$61.14; today's close sits at 95% of that range, 2.1% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — EXEL rises 1.0% to $59.02, a 1-month high
- Closed at $59.02, +0.99% vs the prior close of $58.44. Day range $57.91–$60.08, opened at $58.07.
- Volume was 2.69M shares, 1.1x its 50-day average of 2.37M.
- Price is +5.3% vs its 50-day average ($56.07) and +19.5% vs its 200-day average ($49.40).
- 52-week range $33.76–$61.14; today's close sits at 92% of that range, 3.5% below the 52-week high.
Oct 7, 2026 — EXEL ends flat (+0.2%) to $58.44
- Closed at $58.44, +0.19% vs the prior close of $58.33. Day range $57.88–$59.27, opened at $58.47.
- Volume was 2.37M shares, 1.0x its 50-day average of 2.37M.
- Price is +4.4% vs its 50-day average ($55.99) and +18.5% vs its 200-day average ($49.32).
- 52-week range $33.76–$61.14; today's close sits at 90% of that range, 4.4% below the 52-week high.
Oct 6, 2026 — EXEL dips 0.9% to $58.33
- Closed at $58.33, -0.88% vs the prior close of $58.85. Day range $57.02–$59.00, opened at $58.85.
- Volume was 2.03M shares, 0.9x its 50-day average of 2.38M.
- Price is +4.2% vs its 50-day average ($55.95) and +18.4% vs its 200-day average ($49.25).
- 52-week range $33.76–$61.14; today's close sits at 90% of that range, 4.6% below the 52-week high.
Oct 5, 2026 — EXEL rises 0.8% to $58.85
- Closed at $58.85, +0.79% vs the prior close of $58.39. Day range $57.82–$59.79, opened at $58.36.
- Volume was 2.58M shares, 1.1x its 50-day average of 2.37M.
- Price is +5.3% vs its 50-day average ($55.90) and +19.7% vs its 200-day average ($49.16).
- 52-week range $33.76–$61.14; today's close sits at 92% of that range, 3.7% below the 52-week high.
Oct 2, 2026 — EXEL rises 0.8% to $58.39
- Closed at $58.39, +0.78% vs the prior close of $57.94. Day range $57.94–$58.97, opened at $58.11.
- Volume was 1.97M shares, 0.8x its 50-day average of 2.36M.
- Price is +4.6% vs its 50-day average ($55.83) and +19.0% vs its 200-day average ($49.08).
- 52-week range $33.76–$61.14; today's close sits at 90% of that range, 4.5% below the 52-week high.
EXEL latest news & SEC filings
Every SEC filing by or about EXEL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Beckerle Mary C sold 9,812 shares at $53.66 (≈$526.51K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jul 3, 2026:
- Revenue: $628.69M (prior year $568.26M) (+10.6% vs Jul 4, 2025)
- Net income: $212.05M (prior year $184.85M) (+14.7% vs Jul 4, 2025)
- Diluted EPS: $0.82 (prior year $0.65) (+26.2% vs Jul 4, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade EXEL
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 10, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.10% (largest 3.0%).
- Liquidity: about 2.40M shares (≈$151.09M) trade per day on average.
- 52-week position: $62.83 vs a range of $33.76–$63.31 (98% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 24 sales; latest: Mary C Beckerle sold 9,812 shares on Aug 10, 2026.
- Latest filings: 8-K Sep 11, 2026; 8-K Aug 31, 2026; 10-Q Aug 5, 2026.
- Share count: 247.78M shares outstanding (Jul 27, 2026), -8.0% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
EXEL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 61.69 | 63.31 | 61.28 | 62.83 | 2.77M |
| Oct 14, 2026 | 59.92 | 61.18 | 59.56 | 60.99 | 2.75M |
| Oct 13, 2026 | 60.00 | 60.00 | 58.59 | 59.51 | 2.62M |
| Oct 12, 2026 | 60.48 | 61.66 | 59.80 | 59.82 | 3.13M |
| Oct 9, 2026 | 59.00 | 60.83 | 59.00 | 59.86 | 2.67M |
| Oct 8, 2026 | 58.07 | 60.08 | 57.91 | 59.02 | 2.69M |
| Oct 7, 2026 | 58.47 | 59.27 | 57.88 | 58.44 | 2.37M |
| Oct 6, 2026 | 58.85 | 59.00 | 57.02 | 58.33 | 2.03M |
| Oct 5, 2026 | 58.36 | 59.79 | 57.82 | 58.85 | 2.58M |
| Oct 2, 2026 | 58.11 | 58.97 | 57.94 | 58.39 | 1.97M |
| Oct 1, 2026 | 58.54 | 59.28 | 57.76 | 57.94 | 1.37M |
| Sep 30, 2026 | 58.90 | 61.14 | 58.40 | 58.41 | 3.06M |
| Sep 29, 2026 | 58.06 | 59.13 | 57.53 | 58.65 | 2.24M |
| Sep 28, 2026 | 57.97 | 58.66 | 57.51 | 58.37 | 1.28M |
| Sep 25, 2026 | 58.25 | 58.62 | 57.63 | 58.16 | 1.99M |
| Sep 24, 2026 | 56.70 | 57.99 | 56.58 | 57.95 | 1.93M |
| Sep 23, 2026 | 58.22 | 58.66 | 56.26 | 56.73 | 1.43M |
| Sep 22, 2026 | 57.65 | 59.09 | 57.33 | 58.15 | 1.86M |
| Sep 21, 2026 | 58.61 | 58.81 | 56.90 | 57.22 | 2.10M |
| Sep 18, 2026 | 58.29 | 59.15 | 57.90 | 58.36 | 5.24M |
About Exelixis
Exelixis (EXEL) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in ALAMEDA, CA. State of incorporation: DE. Fiscal year ends January 1. SEC CIK 939767.
EXEL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mary C Beckerle | Director | Aug 12, 2026 |
| Partners Lp Caligan | See Remarks | May 29, 2026 |
| Sue Gail Eckhardt | Director | Jun 3, 2026 |
| Maria C Freire | Director | May 29, 2026 |
| Tomas J. Heyman | Director | May 29, 2026 |
| David Edward Johnson | Director | May 29, 2026 |
| Michael Morrissey | President and CEO | May 19, 2026 |
| Bob Oliver | Director | May 29, 2026 |
| Stelios Papadopoulos | Director | May 29, 2026 |
| George Poste | Director | May 29, 2026 |
| Julie Smith | Director | May 29, 2026 |
| Jack L Wyszomierski | Director | Jun 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dana Aftab | EVP, Research and Development | May 28, 2026 |
| Patrick J. Haley | EVP, Commercial | May 22, 2026 |
| Brenda Hefti | SVP and General Counsel | May 19, 2026 |
| Michael Morrissey | President and CEO | May 19, 2026 |
| Christopher J. Senner | EVP and CFO | May 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 10, 2026 | Mary C Beckerle | Sale | 9,812 | $53.66 |
| Jun 1, 2026 | Sue Gail Eckhardt | Sale | 9,812 | $50.14 |
| Jun 1, 2026 | Jack L Wyszomierski | Sale | 3,925 | $50.55 |
| May 26, 2026 | Dana Aftab | Sale | 43,451 | $50.35 |
| May 20, 2026 | Patrick J. Haley | Sale | 32,110 | $49.81 |
| May 18, 2026 | Christopher J. Senner | Sale | 34,901 | $50.00 |
| May 18, 2026 | Brenda Hefti | Sale | 6,625 | $50.21 |
| May 7, 2026 | Mary C Beckerle | Sale | 7,712 | $48.45 |
| May 7, 2026 | Maria C Freire | Sale | 20,634 | $46.00 |
| May 7, 2026 | George Poste | Sale | 60,000 | $45.71 |
| Feb 24, 2026 | Dana Aftab | Sale | 47,918 | $44.50 |
| Feb 19, 2026 | Dana Aftab | Sale | 29,873 | $44.35 |
| Feb 18, 2026 | Jack L Wyszomierski | Sale | 99,574 | $44.01 |
| Feb 18, 2026 | Julie Smith | Sale | 44,087 | $44.50 |
| Feb 18, 2026 | Julie Smith | Sale | 20,030 | $44.30 |
EXEL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Jan 2, 2026 | $2.32B | $782.57M | 2.78 | $884.27M |
| Jan 3, 2025 | $2.17B | $521.27M | 1.76 | $699.97M |
| Dec 29, 2023 | $1.83B | $207.76M | 0.65 | $333.32M |
| Dec 30, 2022 | $1.61B | $182.28M | 0.56 | $362.61M |
| Dec 31, 2021 | $1.43B | $231.06M | 0.72 | $400.80M |
Latest balance sheet: total assets $2.49B, total liabilities $650.47M, cash $281.45M (as of Jul 3, 2026).
EXEL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $56.70 |
| May 5, 2026 | 8-K Item 2.02 (results) | $44.42 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $42.98 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $44.06 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $37.90 |
| Jul 28, 2025 | 8-K Item 2.02 (results) | $44.39 |
| May 13, 2025 | 8-K Item 2.02 (results) | $36.95 |
| Feb 11, 2025 | 8-K Item 2.02 (results) | $32.81 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $35.30 |
| Oct 29, 2024 | 8-K Item 2.02 (results) | $28.73 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| Apr 30, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on EXEL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.